One session, "Advance and automate cell profiling with Berkeley Lights technology and tools to accelerate cell line engineering and development," will discuss how the Edinburgh Genome Foundry and Beacon Platform have facilitated projects in gene therapy, vaccine development, and metabolic engineering.

The company Lonza will also present on how the firm is using new cell and process technologies for enhancing cell line constructions via Beacon Platforms. Lastly, Berkeley Lights will moderate a panel focusing on the role of advanced screening technologies, automation, and computational tools in accelerating cell line engineering and development projects across academia and industry.

Curia adopts Berkeley Lights platform to accelerate, expand antibody-based drug discovery
Contract research, development, and manufacturing organization Curia has adopted Berkeley Lights’ platform to accelerate and expand its antibody-based...

MImAbs acquires Beacon system of antibody therapeutics
MImAbs has acquired the Berkeley Lights Beacon system via a TechAccess subscription to further the company's mission of generating and validating novel...

Berkeley Lights reports revenue spike in Q2
Berkeley Lights reported an 82% increase in revenue for the second quarter of 2021 compared to the same period a year ago.

Leveraging optofluidics to make therapeutic antibody discovery easier
The need for speed and accuracy in the development of therapeutic antibodies has prompted Berkeley Lights to upgrade its optofluidic tools to help customers...

Abveris expands antibody discovery offerings with second Beacon system
Abveris has starting using a second Berkeley Lights Beacon optofluidic system to enable expansion of its antibody discovery offerings.